Product Highlight - Nilemdo

Add On to Take Back Control: A first-in-class oral, once-daily LDL-C lowering therapy¹

• NILEMDO^® delivered a significant 17-28% reduction in LDL-C^**2-5
• Well tolerated in clinical studies and limited musculoskeletal side effect^1-5
• Can be taken with or without food¹

** vs placebo, on top of maximally tolerated statins with or without other lipid-lowering therapies. An up to 17% LDL-C reduction on top of maximally-tolerated statin therapy with around 50% of studied patients on high-intensity statins.^2,4 An up to 28% LDL-C reduction was observed in patients on no statin or very low-intensity statin therapy, with or without other non-statin lipid-lowering therapies.^3,5

References:
1. NILEMDO^®. HK Prescribing Information Apr 2023.
2. Goldberg AC et al. JAMA. 2019; 322(18): 1780-1788.
3. Laufs U et al. J Am Heart Assoc. 2019; 8:e011662.
4. Ray KK et al. N Engl J Med. 2019; 380: 1022-1032.
5. Ballantyne CM et al. Atherosclerosis. 2018; 277: 195-203.

HK-DAI-NN-2307006; Date of Approval: Jul 2023